Three‐Year Outcomes from BENEFIT, a Randomized, Active‐Controlled, Parallel‐Group Study in Adult Kidney Transplant Recipients

The clinical profile of belatacept in kidney transplant recipients was evaluated to determine if earlier results in the BENEFIT study were sustained at 3 years. BENEFIT is a randomized 3 year, phase III study in adults receiving a kidney transplant from a living or standard criteria deceased donor....

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of transplantation 2012-01, Vol.12 (1), p.210-217
Hauptverfasser:	Vincenti, F., Larsen, C. P., Alberu, J., Bresnahan, B., Garcia, V. D., Kothari, J., Lang, P., Urrea, E. Mancilla, Massari, P., Mondragon‐Ramirez, G., Reyes‐Acevedo, R., Rice, K., Rostaing, L., Steinberg, S., Xing, J., Agarwal, M., Harler, M. B., Charpentier, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Abatacept Adult Belatacept Biological and medical sciences cyclosporine Cyclosporine - therapeutic use Glomerular Filtration Rate Graft Survival Humans Immunoconjugates - therapeutic use Immunosuppressive Agents - therapeutic use kidney Kidney Transplantation Medical sciences renal function Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!